Nguyen PHA, Fukushi S, Yamada S, Harada S, Yoshikawa T, Kinoshita H, Kawahara M, Ogawa T, Ebihara H, Moi ML, Saijo M. Analysis of antiviral drug properties of thymidine kinase of herpes B virus using recombinant herpes simplex virus 1.
Microbiol Spectr 2024;
12:e0309123. [PMID:
38095468 PMCID:
PMC10783082 DOI:
10.1128/spectrum.03091-23]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 11/25/2023] [Indexed: 01/13/2024] Open
Abstract
IMPORTANCE
Zoonotic infection of humans with herpes B virus (BV) causes severe neurological diseases. Acyclovir (ACV) and ganciclovir (GCV), most frequently used as anti-herpes drugs, are recommended for prophylaxis and therapy in human BV infection. In this study, we examined the property of BV thymidine kinase (TK) against anti-herpes drugs using a recombinant herpes simplex virus type 1 (HSV-1) carrying BV TK gene. We found that HSV-1 carrying BV TK was similarly sensitive to GCV as HSV-1 carrying varicella zoster virus TK. In addition, we demonstrated that BV TK was not mutated in the GCV- and ACV-resistant HSV-1 carrying BV TK, suggesting that ACV- or GCV-resistant BV might be rare during treatment with these antiviral drugs. These data can provide a new insight into the properties of BV TK in terms of the development of drug resistance.
Collapse